Oculis Holding AG (ICE:OCS)

Market Cap	128.46B
Revenue (ttm)	116.31M
Net Income (ttm)	-16.36B
Shares Out	n/a
EPS (ttm)	-353.47
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	47,296
Average Volume	83,958
Open	2,430.00
Previous Close	2,480.00
Day's Range	2,400.00 - 2,500.00
52-Week Range	1,800.00 - 3,300.00
Beta	0.13
RSI	45.89
Earnings Date	Nov 10, 2025

About Oculis Holding AG

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 49
• Stock Exchange: Nasdaq Iceland
• Ticker Symbol: OCS

Financial Performance

In 2024, Oculis Holding AG's revenue was 686,000, a decrease of -22.31% compared to the previous year's 883,000. Losses were -85.78 million, -3.41% less than in 2023.

Financial numbers in CHF